Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 19;79(9):883-885.
doi: 10.1136/thorax-2023-220402.

Antibiotic pharmacokinetics in infected pleural effusions

Affiliations

Antibiotic pharmacokinetics in infected pleural effusions

David T Arnold et al. Thorax. .

Abstract

Pleural infection is usually treated with empirical broad-spectrum antibiotics, but limited data exist on their penetrance into the infected pleural space. We performed a pharmacokinetic study analysing the concentration of five intravenous antibiotics across 146 separate time points in 35 patients (amoxicillin, metronidazole, piperacillin-tazobactam, clindamycin and cotrimoxazole). All antibiotics tested, apart from co-trimoxazole, reach pleural fluid levels equivalent to levels within the blood and well above the relevant minimum inhibitory concentrations. The results demonstrate that concerns about the penetration of commonly used antibiotics, apart from co-trimoxazole, into the infected pleural space are unfounded.

Keywords: Bacterial Infection; Pleural Disease; Pneumonia; Respiratory Infection.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Mean (±SD) intravenous antibiotic concentration-time curves in the blood (dotted line) and pleural fluid (solid line): (A) amoxicillin, (B) metronidazole, (C) piperacillin (piperacillin-tazobactam), (D) tazobactam (piperacillin-tazobactam), (E) trimethoprim (co-trimoxazole), (F) sulphamethoxazole (co-trimoxazole) and (G) clindamycin. Minimum inhibitory concentrations (MICs) (EUCAST) of amoxicillin: Staphylococcus aureus 1 mg/L, Haemophilus influenza 2 mg/L, Streptococcus Milleri group 0.125 mg/L and Streptococcus pneumoniae 0.06 mg/L. MICs (EUCAST) of metronidazole: prevotella 1 mg/L, Gram-positive anaerobes (class) 0.25 mg/L and fusobacterium 0.125 mg/L. MICs (EUCAST) of piperacillin-tazobactam: S. aureus 2 mg/L, H. influenza 0.5 mg/L, Streptococcus Milleri group 1 mg/L, Escherichia coli 8 mg/L and S. pneumoniae 0.064 mg/L. MICs (EUCAST) of trimethoprim-sulfamethoxazole: S. aureus 0.25 mg/L, H. influenza 0.5 mg/L, S. pneumoniae 1 mg/L, E. coli 0.5 mg/L. MICs (EUCAST) of clindamycin: S. aureus 0.25 mg/L, Streptococcus Milleri group 0.25 mg/L and S. pneumoniae 0.25 mg/L. The MICs listed for common causative organisms are derived from the EUCAST website (https://www.eucast.org/mic_distributions_and_ecoffs/), which describes the MIC of ‘wild-type’ and, therefore, fully sensitive bacteria.

References

    1. Arnold DT, Hamilton FW, Morris TT, et al. . Epidemiology of pleural empyema in english hospitals and the impact of influenza. Eur Respir J 2021;57:2003546. 10.1183/13993003.03546-2020 - DOI - PMC - PubMed
    1. Lau EPM, Sidhu C, Popowicz ND, et al. . Pharmacokinetics of antibiotics for pleural infection. Expert Rev Respir Med 2022;16:1057–66. 10.1080/17476348.2022.2147508 - DOI - PubMed
    1. Davies HE, Davies RJO, Davies CWH, et al. . Management of pleural infection in adults: British thoracic society pleural disease guideline 2010. Thorax 2010;65:ii41–53. 10.1136/thx.2010.137000 - DOI - PubMed
    1. Felton TW, McCalman K, Malagon I, et al. . Pulmonary penetration of piperacillin and tazobactam in critically ill patients. Clin Pharmacol Ther 2014;96:438–48. 10.1038/clpt.2014.131 - DOI - PMC - PubMed
    1. Bhatnagar R, Skouras V, Rahman N, et al. . Antibiotics for pleural infections. Eur Respir Monogr 2017;75:253–63. 10.1183/2312508X.erm7517 - DOI

Publication types

Substances